GlassScriptPhysician profile
Esther Kim
NPI 1649835661
$3,158.23
in general payments reported to CMS, 2019-2025
15 companies · $1,182 in 2025
The $1,182 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $28.59 · 2021: $186 · 2022: $1,513 · 2023: $88.44 · 2024: $41.65 · 2025: $1,182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,158 · Food and Beverage: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,158.34 |
| Food and Beverage | $153.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,263.99 | 2022-2025 | |
| Scynexis, INC. | $1,149.48 | 2022 | |
| Novo Nordisk INC | $141.79 | 2019-2025 | Wegovy |
| Dexcom, INC. | $133.75 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $111.28 | 2021-2024 | Camzyos |
| Janssen Pharmaceuticals, INC | $110.27 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.10 | 2022-2023 | Jardiance |
| Abbvie INC. | $28.59 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.53 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.45 | 2023 | |
| Horizon Therapeutics Plc | $24.87 | 2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $19.61 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $17.57 | 2021 | |
| Tactile Systems Technology INC | $16.86 | 2024 | Flexitouch Plus, Entre Plus |
| Pfizer INC. | $14.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Esther Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.